Search Results

You are looking at 1 - 7 of 7 items for :

  • "certolizumab" x
Clear All

Vollenhoven, R. F. és mtsai: Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann. Rheum. Dis., 2009, 68 , 805

Restricted access

838 Nesbitt, A., Fossatti, G., Bergin, M. és mtsai: Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor α agents

Restricted access
Orvosi Hetilap
Authors: Zoltán Hella, László Hodinka, Piroska Turbucz and Gábor László Kovács

, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional

Restricted access
Orvosi Hetilap
Authors: Lajos Sándor Kiss, Tamás Szamosi, Tamás Molnár, Pál Miheller, László Lakatos, Áron Vincze, Károly Palatka, Zsolt Bartha, Beáta Gasztonyi, Ágnes Salamon, Gábor Horváth, Gábor Tamás Tóth, Klaudia Farkas, János Banai, Zsolt Tulassay, Ferenc Nagy, Mária Szenes, Gábor Veres, Barbara Dorottya Lovász, Zsuzsanna Végh, Petra Anna Golovics, Miklós Szathmári, Mária Papp and Péter László Lakatos

829 838 Sandborn, W. J., Feagan, B. G., Stoinov, S. és mtsai: Certolizumab pegol for the treatment of Crohn’s disease. N. Engl. J. Med., 2007, 357 , 228

Open access

. Lichtenstein GR , Thomsen OØ , Schreiber S , Lawrance IC , Hanauer SB , Hanauer SB , Bloomfield R , Sandborn WJ : Precise 3 Study Investigators: Continuous therapy with certolizumab pegol maintains remission of patients

Open access
Orvosi Hetilap
Authors: Katalin Lőrinczy, Pál Miheller, Sándor Lajos Kiss and Péter László Lakatos

., Lawrance, I. C., et al.: Maintenance therapy with certolizumab pegol for Crohn’s disease. N. Engl. J. Med., 2007, 357 , 239–250. Lawrance I. C. Maintenance therapy with certolizumab

Open access

818 824 Schreiber, S., Rutgeerts, P., Fedorak, R. N. és mtsai, CDP870 Crohn’s Disease Study Group: A randomized, placebo-controlled trial of certolizumab pegol

Open access